phrykt

GENELUX Corp (GNLX): who owns it and who trades it

As of Nov 16, 2026, GNLX insiders reported 25 open-market sales worth $368K and no purchases in the last 12 months, with 30% of the sale value made under pre-set 10b5-1 plans. The largest seller was Thomas Zindrick (CEO), with $148K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling GENELUX

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns GNLX

72 funds and institutions reported GNLX shares worth $29.6M at the end of Q2 2026, about 22% of the company. The largest holder is Woodward Diversified Capital, LLC with 5.0%.

Funds and institutions (13F) 22%Everyone else 78%

10 largest owners, by share of the company

Woodward Diversified Capital, LLC5.0%
Vanguard Capital Management LLC3.7%
Bleichroeder LP3.1%
BlackRock, Inc.1.0%
Geode Capital Management, LLC1.0%
CM Management, LLC0.9%
Bank of America Corp0.7%
Vanguard Fiduciary Trust Co0.5%
Flputnam Investment Management Co0.5%
Global Retirement Partners, LLC0.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Woodward Diversified Capital, LLC2.26M5.05%$6.8M+7%
Vanguard Capital Management LLC1.68M3.74%$5M-1%
Bleichroeder LP1.38M3.08%$4.2MNo change
BlackRock, Inc.439,6020.98%$1.3M+8%
Geode Capital Management, LLC439,2130.98%$1.3M-3%
CM Management, LLC400,0000.89%$1.2M+60%
Bank of America Corp328,8030.73%$990K+2%
Vanguard Fiduciary Trust Co236,3440.53%$711K-6%
Flputnam Investment Management Co231,4050.52%$697K-18%
Global Retirement Partners, LLC227,8540.51%$686KNew
LPL Financial LLC157,8570.35%$475K+14%
State Street Corp145,8500.33%$439KNo change
Provident Wealth Management, LLC144,9080.32%$436K-7%
LifeSteps Financial, Inc.121,9650.27%$367K+3%
Osaic Holdings, Inc.121,9580.27%$367K+2%
Renaissance Technologies LLC105,2290.23%$317K+763%
Northern Trust Corp89,2790.20%$269K-46%
Citadel Advisors LLC85,4810.19%$257KNew
Morgan Stanley83,5430.19%$251K-5%
SteelPeak Wealth, LLC75,8950.17%$228K+25%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, GNLX insiders reported $0 of open-market purchases and $368K of sales. 30% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$368K
25 trades, 6 people
Sales under a 10b5-1 plan
30%
Share of sale value
Latest trade
Nov 3, 2026
Filed Nov 5, 2026

Purchases and sales by month

$160K$160KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 3, 2026Joseph CappelloChief Technical OfficerSale668$2.04$1.4KForm 4
Nov 3, 2026Yong YuChief Scientific OfficerSale668$2.01$1.3KForm 4
Nov 3, 2026Thomas ZindrickCEOSale3,089$2.05$6.3KForm 4
Aug 31, 2026Joseph CappelloChief Technical OfficerSale10,257$2.74$28.1KForm 4
Aug 31, 2026Thomas ZindrickCEOSale34,463$2.67$92KForm 4
Aug 31, 2026Yong YuChief Scientific OfficerSale9,683$2.75$26.6KForm 4
Aug 4, 2026Yong YuChief Scientific OfficerSale653$2.94$1.9KForm 4
Aug 4, 2026Joseph CappelloChief Technical OfficerSale653$2.95$1.9KForm 4
Aug 4, 2026Thomas ZindrickCEOSale3,023$2.95$8.9KForm 4
Jul 1, 2026John W SmitherDirectorSale12,000$2.91$34.9KForm 4
Jun 3, 2026Ralph SmallingHead of RegulatorySale192$2.93$563Form 4
Jun 1, 2026John ThomasDirectorSale plan10,000$2.98$29.8KForm 4
May 11, 2026Joseph CappelloChief Technical OfficerSale605$2.97$1.8KForm 4
May 11, 2026Thomas ZindrickCEOSale2,798$2.94$8.2KForm 4
May 11, 2026Ralph SmallingHead of RegulatorySale270$2.98$805Form 4
Mar 25, 2026Ralph SmallingHead of RegulatorySale240$2.51$602Form 4
Mar 24, 2026Ralph SmallingHead of RegulatorySale345$2.42$835Form 4
Mar 24, 2026Joseph CappelloChief Technical OfficerSale906$2.42$2.2KForm 4
Mar 24, 2026Thomas ZindrickCEOSale3,582$2.42$8.7KForm 4
Mar 2, 2026John ThomasDirectorSale plan10,000$2.90$29KForm 4
Dec 5, 2025Ralph SmallingHead of RegulatorySale165$4.69$774Form 4
Dec 1, 2025John ThomasDirectorSale plan10,000$5.00$50KForm 4
Nov 17, 2025Thomas ZindrickCEOSale4,509$5.37$24.2KForm 4
Nov 17, 2025Yong YuVice presidentSale973$5.37$5.2KForm 4
Nov 17, 2025Ralph SmallingHead of RegulatorySale343$5.37$1.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Thomas ZindrickPresident and CEO–$148KNov 3, 2026
John ThomasDirector–$109KJun 1, 2026
Joseph CappelloChief Technical Officer–$35.4KNov 3, 2026
Yong YuSVP, Clinical Development–$35.1KNov 3, 2026
John W SmitherDirector–$34.9KJul 1, 2026
Ralph SmallingHead of Regulatory–$5.4KJun 3, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

GNLX short interest

High short interest. 10.0% of GNLX shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 53%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.53M GNLX shares were sold short, 10.0% of the shares outstanding, down 2.4% from the report before. At the average daily volume of 544,594 shares, buying them all back would take about 8.3 trading days (days to cover).

Shares short, % of all shares

10.0%May 15Oct 3010.8%

Days to cover

8.3May 15Oct 3026.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.53M10.01%-2%544,5948.3
Oct 15, 20264.64M10.26%+6%295,50915.7
Sep 30, 20264.36M9.64%+6%213,48720.4
Sep 15, 20264.10M9.05%+8%284,33114.4
Aug 31, 20263.78M8.34%+7%354,59510.7
Aug 14, 20263.52M7.78%+14%416,1848.4
Jul 31, 20263.08M6.88%-1%152,99920.1
Jul 15, 20263.11M6.95%+4%174,00417.9
Jun 30, 20263.01M6.71%-6%234,81412.8
Jun 15, 20263.18M7.11%+1%152,09420.9
May 29, 20263.14M7.00%+6%130,95223.9
May 15, 20262.96M6.60%-6%196,17315.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

GENELUX company events

GENELUX filed 6 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Jun 22, 2026.

  1. Jun 22, 2026VoteReported shareholder vote results. Filing
  2. Mar 19, 2026AgreementGenelux Corporation entered into a Sales Agreement with TD Securities (USA) LLC, pursuant to which the Company may, from time to time, offer and sell shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $100 million, through TD Cowen, acting… Filing
  3. Feb 2, 2026AnnouncementShared information with investors. Filing
  4. Jan 8, 2026AnnouncementGenelux Corporation entered into an underwriting agreement with Lucid Capital Markets, LLC ( the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten offering an aggregate of 6,666,667 shares of the Company’s common stock, par value $0.001 per share, at a price… Filing
  5. Jan 5, 2026AnnouncementGenelux reported interim results from two ongoing trials evaluating systemic (intravenous) administration of Olvi-Vec in patients with progressive small cell lung cancer and progressive non-small cell lung cancer, respectively, after failure of prior platinum-based regimens. Filing
  6. Jan 2, 2026LeadershipPaul Scigalla, M.D. resigned as Chief Medical Officer of Genelux Corporation, effective immediately. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

GENELUX financials

Famous investors that hold GNLX

4 of the 50 well-known investors we track reported holding GNLX in their latest 13F filing. The largest position is Jim Simons's, worth $253K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202699,811$253K0.0%-5%
Ken Griffin · Citadel AdvisorsQ3 202698,578$249K0.0%+15%
Steve Cohen · Point72 Asset ManagementQ3 202620,858$52.8K0.0%-11%
Israel Englander · Millennium ManagementQ3 202618,065$45.7K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named GNLX in the last 120 days.

FiledHolderFormStake
Nov 4, 2026Aladar Szalay13G/A6.2%
Nov 4, 2026Aladar Szalay13G/A6.2%

Questions about GENELUX Corp (GNLX) stock

Who owns the most GNLX stock?

The largest reported owner of GENELUX Corp (GNLX) is Woodward Diversified Capital, LLC, with 5.0% of the company. In total, 72 funds and institutions reported holding GNLX at the end of Q2 2026, together about 22% of the shares. See the largest owners.

Are GNLX insiders buying or selling?

In the last 12 months, GNLX insiders reported no open-market purchases and 25 sales worth $368K. The latest trade was on Nov 3, 2026. See every trade.

What is the short interest in GNLX?

As of Oct 30, 2026, 4.53M GNLX shares were sold short, 10.0% of the shares outstanding, down 2.4% from the report before. At the average daily volume of 544,594 shares, buying them all back would take about 8.3 trading days (days to cover). See the history.

Which famous investors hold GNLX?

4 of the 50 well-known investors we track reported GNLX in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $253K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.